| PH |
Report |
Adjusted EPS (FQ4'26) |
BEAT |
pred ~$8.30 vs. cons ~$8.18 |
MEDIUM |
| PH |
Report |
Total revenue (FQ4'26) |
IN-LINE |
pred ~$5.53B vs. cons ~$5.50B |
MEDIUM |
| PH |
Report |
Adj. segment operating margin (FQ4'26) |
BEAT |
pred ~27.6% vs. cons ~27.4% |
MEDIUM |
| PH |
Guide |
Initial FY27 adjusted EPS guide |
LOWER |
guide ~$33.00 (midpoint) vs. cons ~$34.20 (FY27) |
MEDIUM |
| PH |
Guide |
Initial FY27 organic sales growth guide |
UNCHANGED |
guide ~4-5% vs. cons ~5% (FY27) |
MEDIUM |
| PH |
Guide |
FY26 full-year adjusted EPS (confirm) |
BETTER |
guide ~$31.35 vs. cons ~$31.20 (FY26) |
HIGH |
| PH |
Guide |
FY27 adj. segment margin outlook |
BETTER |
guide ~27.5-28% vs. cons ~27.4% (FY27) |
LOW |
| PH |
Guide |
Filtration Group deal timing/FY27 inclusion |
UNKNOWN |
guide close ~Nov'26, likely ex-deal FY27 base vs. cons assumes ~$9.25B/close by FY27 (FY27) |
LOW |
| PH |
Return |
Day-1 residual (stock − beta × S&P 500) |
-2.5% |
— |
MEDIUM |
| PH |
Return |
5-day cumulative residual |
-3.5% (FADE) |
Q4 beat is fully telegraphed (management guided it in April), so the print is a non-event; the swing factor is the initial FY27 guide, which PH historically sets conservatively and likely lands below Street EPS (and ex-Filtration), implying out-period estimate resets. With the stock at all-time highs (~$997, +40% y/y) and full valuation — plus the precedent of a ~4% drop after the record Q3 beat-and-raise — elevated expectations leave asymmetric downside. Out-period math (conservative FY27 anchor pulling FY27 numbers down even after a Q4 beat) drives continued fade over the week barring a decisively above-consensus FY27 organic/EPS framing. |
MEDIUM |